Daily non-political popular news in brief.

Patient with rare disorder responds to cancer drug

02-13-2008 · EurekAlert!

A rare disorder caused by an excess of two types of immune cells -- the mast cell found in various tissues and its blood-based twin, the basophil -- has successfully been treated with a cancer drug, report scientists from NIAID.

Keywords: patient, rare, disorder, responds, cancer, drug, respond

« Previous | Next »

Similar news on "Patient with rare disorder responds to cancer drug":

Common cause of heart disease, diabetes may be treatable with malaria drug
11-07-2006 · EurekAlert!
Studies of a rare genetic condition that increases cancer risk have unveiled a potential treatment for metabolic syndrome, a common disorder that afflicts as many as one in every four American adults and puts them at sharply increased risk of type 2 diabetes and clogged arteries.
Similar news · Read more »
UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
01-31-2008 · EurekAlert!
Researchers at UCLA's Jonsson Cancer Center have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva.
Similar news · Read more »
A chemotherapy drug packs a one-two punch
02-20-2007 · EurekAlert!
How cancer cells are killed could turn out to be an important element in activating a patient's immune system. A new study shows that one chemotherapy drug may kill tumor cells in such a way that the immune system can recognize the cancerous cells and help fight the disease more effectively.
Similar news · Read more »
Eculizumab is well-tolerated and shows significant improvement in PNH patients (Ph III)
12-09-2006 · EurekAlert!
Eculizumab, a MAb drug, appeared safe and well-tolerated, and provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH) in a Phase 3 open-label, 52 weeks of treatment trial. PNH is a rare and life-threatening form of hemolytic anemia and acquired genetic blood disorder, and patients lack naturally-occurring complement inhibitors on the surface of their red blood cells.
Similar news · Read more »
SCAI issues clinical alert on drug-eluting stents and late thrombosis
01-11-2007 · EurekAlert!
The Society for Cardiovascular Angiography and Interventions (SCAI) today released a clinical alert advising physicians on practical steps for reducing the risk of a rare but serious complication associated with drug-eluting stents. The document follows hearings held by the FDA's Circulatory Systems Device Panel. SCAI's clinical alert focuses on careful patient selection, meticulous stent implantation, and consistent use of medications to prevent the delayed formation of blood clots that can block blood flow to the heart.
Similar news · Read more »
Genes and biomarkers that allow doctors to choose the right therapy for the right patient
04-17-2007 · EurekAlert!
Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers. Now, researchers have the tools and the knowledge to help predict how individuals will respond to cancer therapies, enabling them to create more effective therapies for individual cancers -- personalized medicine.
Similar news · Read more »
MIT model could predict cells' response to drugs
07-30-2007 · EurekAlert!
MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices and drug developers identify the ideal compound. In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including cancer, arthirtis, and immune system disorders.
Similar news · Read more »
A new target for the treatment of breast cancer
01-11-2007 · EurekAlert!
The active ingredient in a drug currently being tested to treat rheumatoid arthritis might also one day serve as an effective means of treating one of the deadliest forms of breast cancer. Berkeley Lab researchers have demonstrated that inhibiting the activity of the protease enzyme known as TACE can deprive tumor cells of a key factor needed for their proliferation. TACE is strongly present in a form of breast cancer which responds poorly to current therapies.
Similar news · Read more »
Study finds heart failure is rare among leukemia patients on imatinib
09-06-2007 · EurekAlert!
Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at the University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.
Similar news · Read more »
Mouse Tests Predict Drug Response In Relapsing Pancreatic Cancer Patients
10-12-2006 · ScienceDaily
By slicing up bits of patient tumors and grafting them into mice, Johns Hopkins Kimmel Cancer Center specialists have figured out how to accurately 'test drive' chemotherapy drugs to learn in advance which drug treatments offer each individual pancreatic cancer patient the best therapeutic journey.
Similar news · Read more »